Ser142
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser142  -  DBN1 (human)

Site Information
NGLARLssPVLHRLR   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 452446

In vivo Characterization
Methods used to characterize site in vivo:
[32P] ATP in vitro ( 17 ) , immunoprecipitation ( 2 ) , mass spectrometry ( 1 , 2 , 4 , 5 , 7 , 8 , 9 , 10 , 11 , 13 , 14 , 15 , 16 , 18 , 19 , 20 , 21 , 22 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 ) , mass spectrometry (in vitro) ( 17 ) , microscopy-colocalization with upstream kinase ( 17 ) , mutation of modification site ( 2 , 17 , 20 ) , peptide sequencing ( 3 ) , phospho-antibody ( 2 , 20 ) , western blotting ( 2 , 3 , 20 )
Disease tissue studied:
breast cancer ( 13 , 27 , 28 ) , luminal A breast cancer ( 5 ) , luminal B breast cancer ( 5 ) , breast cancer, surrounding tissue ( 5 ) , breast cancer, triple negative ( 5 ) , cervical cancer ( 63 ) , cervical adenocarcinoma ( 63 ) , gastric cancer ( 75 ) , gastric carcinoma ( 75 ) , leukemia ( 29 , 34 , 50 , 51 ) , acute myelogenous leukemia ( 29 , 34 ) , acute erythroid leukemias, including erythroleukemia (M6a) and very rare pure erythroid leukemia (M6b) ( 26 , 29 ) , acute megakaryoblastic leukemia (M7) ( 26 ) , acute monoblastic leukemia (M5a) or acute monocytic leukemia (M5b) ( 26 ) , acute myeloblastic leukemia, with granulocytic maturation (M2) ( 26 ) , acute myeloblastic leukemia, without maturation (M1) ( 26 ) , chronic myelogenous leukemia ( 50 , 51 ) , hepatocellular carcinoma, surrounding tissue ( 62 ) , lung cancer ( 10 , 19 , 28 , 40 , 45 , 60 , 76 , 81 ) , non-small cell lung cancer ( 28 , 60 , 76 , 81 ) , non-small cell lung adenocarcinoma ( 10 , 19 , 40 , 81 ) , non-small cell squamous cell lung carcinoma ( 81 ) , lymphoma ( 14 ) , B cell lymphoma ( 26 ) , Burkitt's lymphoma ( 14 ) , non-Hodgkin's lymphoma ( 26 ) , follicular lymphoma ( 14 ) , mantle cell lymphoma ( 14 ) , neuroblastoma ( 17 , 25 ) , pancreatic ductal adenocarcinoma ( 18 ) , multiple myeloma ( 26 ) , prostate cancer ( 3 ) , melanoma skin cancer ( 4 , 9 ) , FTLD ( 44 )
Relevant cell line - cell type - tissue:
'brain, cerebral cortex' ( 44 ) , 'brain, embryonic' ( 20 ) , 'muscle, skeletal' ( 35 ) , 'pancreatic, ductal'-pancreas ( 18 ) , 293 (epithelial) [AT1 (human), transfection, AT1R stable transfected HEK293] ( 53 ) , 293 (epithelial) ( 72 ) , 293E (epithelial) ( 37 ) , 786-O (renal) [VHL (human), transfection] ( 7 ) , 786-O (renal) ( 7 ) , A498 (renal) ( 54 ) , A549 (pulmonary) ( 21 ) , AML-193 (monocyte) ( 26 , 29 ) , BJAB (B lymphocyte) ( 14 ) , breast ( 5 ) , BT-20 (breast cell) ( 28 ) , BT-549 (breast cell) ( 28 ) , Calu 6 (pulmonary) ( 28 ) , CL1-0 (pulmonary) ( 45 ) , CL1-1 (pulmonary) ( 45 ) , CL1-2 (pulmonary) ( 45 ) , CL1-5 (pulmonary) ( 45 ) , CMK (megakaryoblast) ( 26 ) , COS (fibroblast) ( 20 , 85 ) , COS7 (fibroblast) ( 17 ) , CTS (myeloid) ( 26 ) , DG75 (B lymphocyte) ( 47 ) , DOHH2 ('B lymphocyte, precursor') ( 26 ) , DU 145 (prostate cell) ( 3 ) , fibroblast-skin ( 87 ) , FL-318 (B lymphocyte) ( 14 ) , Flp-In T-Rex-293 (epithelial) [PRKD1 (human), genetic knockin] ( 30 ) , Flp-In T-Rex-293 (epithelial) ( 30 ) , H2009 (pulmonary) ( 28 ) , H2077 (pulmonary) ( 28 ) , H2887 (pulmonary) ( 28 ) , H322M (pulmonary) ( 28 ) , HCC1359 (pulmonary) ( 28 ) , HCC1937 (breast cell) ( 28 ) , HCC2279 (pulmonary) ( 28 ) , HCC366 (pulmonary) ( 28 ) , HCC4006 (pulmonary) ( 28 ) , HCC78 (pulmonary) ( 28 ) , HCC827 (pulmonary) ( 28 ) , HCT116 (intestinal) ( 73 ) , HEK293T (epithelial) ( 2 , 8 , 86 ) , HEL (erythroid) ( 26 , 29 ) , HeLa (cervical) ( 11 , 24 , 43 , 64 , 73 , 74 , 77 , 79 , 80 , 82 , 84 , 88 ) , HeLa S3 (cervical) ( 41 , 63 ) , hepatocyte-liver ( 62 ) , HepG2 (hepatic) ( 68 , 70 ) , HMLER ('stem, breast cancer') [CXCR4 (human), knockdown] ( 13 ) , HMLER ('stem, breast cancer') ( 13 ) , HOP62 (pulmonary) ( 28 ) , hTERT-RPE1 (epithelial) ( 2 ) , HUES-7 ('stem, embryonic') ( 71 ) , HUES-9 ('stem, embryonic') ( 42 ) , JEKO-1 (B lymphocyte) ( 14 ) , Jurkat (T lymphocyte) ( 22 , 33 , 36 , 38 , 39 , 46 , 48 , 49 , 52 , 61 ) , K562 (erythroid) ( 24 , 50 , 51 , 64 ) , Kasumi-1 (myeloid) ( 26 ) , KG-1 (myeloid) ( 26 , 34 ) , LCLC-103H (pulmonary) ( 28 ) , liver ( 16 ) , LNCaP (prostate cell) ( 3 ) , LOU-NH91 (squamous) ( 28 ) , lung ( 19 ) , MCF-7 (breast cell) ( 28 ) , MDA-MB-231 (breast cell) ( 28 ) , MDA-MB-468 (breast cell) ( 28 ) , MKN-45 (gastric) ( 75 ) , MV4-11 (macrophage) ( 26 ) , NB10 (neural crest) ( 25 ) , NCI-H1299 (pulmonary) ( 76 ) , NCI-H1395 (pulmonary) ( 28 ) , NCI-H1568 (pulmonary) ( 28 ) , NCI-H157 (pulmonary) ( 28 ) , NCI-H1648 (pulmonary) ( 28 ) , NCI-H1650 (pulmonary) ( 60 ) , NCI-H1666 (pulmonary) ( 28 ) , NCI-H1703 (squamous) ( 81 ) , NCI-H2030 (pulmonary) ( 28 ) , NCI-H2172 (pulmonary) ( 28 ) , NCI-H2228 (pulmonary) ( 67 , 69 ) , NCI-H322 (pulmonary) ( 28 ) , NCI-H3255 (pulmonary) ( 65 , 66 ) , NCI-H460 (pulmonary) ( 28 , 73 ) , NCI-H520 (squamous) ( 28 ) , NCI-H647 (pulmonary) ( 28 ) , Neuro-2a (neuron) ( 17 ) , NPC (neural crest) ( 25 ) , OCI-ly1 (B lymphocyte) ( 14 ) , OPM-2 (plasma cell) ( 26 ) , P31/FUJ (erythroid) ( 26 ) , PC3 (prostate cell) ( 3 ) , PC9 (pulmonary) ( 10 , 28 ) , PC9-IR (pulmonary) ( 10 ) , platelet-blood ( 83 ) , REC-1 (B lymphocyte) ( 14 ) , RL ('B lymphocyte, precursor') ( 26 ) , RPMI-8266 (plasma cell) ( 26 ) , SH-SY5Y (neural crest) [LRRK2 (human), transfection, over-expression of LRRK2(G2019S)] ( 15 ) , SH-SY5Y (neural crest) ( 15 ) , SKBr3 (breast cell) ( 27 ) , skin ( 4 ) , SU-DHL-4 (B lymphocyte) ( 14 ) , SU-DHL-6 (B lymphocyte) ( 26 ) , TERT20 ('stem, mesenchymal') ( 78 ) , U-1810 (pulmonary) [EFNB3 (human), knockdown] ( 40 ) , U-1810 (pulmonary) ( 40 ) , U266 (plasma cell) ( 26 ) , Vero E6-S ('epithelial, kidney') ( 1 ) , WM239A (melanocyte) ( 9 )

Upstream Regulation
Putative in vivo kinases:
CDK5 (human) ( 2 , 17 )
Kinases, in vitro:
CDK5 (human) ( 17 , 20 )
Putative upstream phosphatases:
CDC14A (human) ( 2 )
Phosphatases, in vitro:
CDC14A (human) ( 2 )
Treatments:
BI2536 ( 43 ) , CXCL12 ( 3 ) , nocodazole ( 63 )

Downstream Regulation
Effects of modification on DBN1:
intracellular localization ( 2 , 17 ) , molecular association, regulation ( 20 )
Effects of modification on biological processes:
cytoskeletal reorganization ( 2 , 17 , 20 )
Induce interaction with:
ACTB (human) ( 20 ) , EB3 (human) ( 20 )

Disease / Diagnostics Relevance
Relevant diseases:
prostate cancer ( 3 )

References 

1

Bouhaddou M, et al. (2020) The Global Phosphorylation Landscape of SARS-CoV-2 Infection. Cell
32645325   Curated Info

2

Uddin B, et al. (2019) The human phosphatase CDC14A modulates primary cilium length by regulating centrosomal actin nucleation. EMBO Rep 20
30467237   Curated Info

3

Dart AE, et al. (2017) The drebrin/EB3 pathway drives invasive activity in prostate cancer. Oncogene 36, 4111-4123
28319065   Curated Info

4

Bassani-Sternberg M, et al. (2016) Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry. Nat Commun 7, 13404
27869121   Curated Info

5

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

6

Boeing S, et al. (2016) Multiomic Analysis of the UV-Induced DNA Damage Response. Cell Rep 15, 1597-1610
27184836   Curated Info

7

Malec V, Coulson JM, Urbé S, Clague MJ (2015) Combined Analyses of the VHL and Hypoxia Signaling Axes in an Isogenic Pairing of Renal Clear Cell Carcinoma Cells. J Proteome Res 14, 5263-72
26506913   Curated Info

8

Franchin C, et al. (2015) Quantitative analysis of a phosphoproteome readily altered by the protein kinase CK2 inhibitor quinalizarin in HEK-293T cells. Biochim Biophys Acta 1854, 609-23
25278378   Curated Info

9

Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615
25850435   Curated Info

10

Tsai CF, et al. (2015) Large-scale determination of absolute phosphorylation stoichiometries in human cells by motif-targeting quantitative proteomics. Nat Commun 6, 6622
25814448   Curated Info

11

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

12

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

13

Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90
24782546   Curated Info

14

Rolland D, et al. (2014) Global phosphoproteomic profiling reveals distinct signatures in B-cell non-Hodgkin lymphomas. Am J Pathol 184, 1331-42
24667141   Curated Info

15

Luerman GC, et al. (2014) Phosphoproteomic evaluation of pharmacological inhibition of leucine-rich repeat kinase 2 reveals significant off-target effects of LRRK-2-IN-1. J Neurochem 128, 561-76
24117733   Curated Info

16

Bian Y, et al. (2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics 96, 253-62
24275569   Curated Info

17

Tanabe K, et al. (2014) Phosphorylation of drebrin by cyclin-dependent kinase 5 and its role in neuronal migration. PLoS One 9, e92291
24637538   Curated Info

18

Britton D, et al. (2014) Quantification of pancreatic cancer proteome and phosphorylome: indicates molecular events likely contributing to cancer and activity of drug targets. PLoS One 9, e90948
24670416   Curated Info

19

Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96
23911959   Curated Info

20

Worth DC, et al. (2013) Drebrin contains a cryptic F-actin-bundling activity regulated by Cdk5 phosphorylation. J Cell Biol 202, 793-806
23979715   Curated Info

21

Kim JY, et al. (2013) Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells. Proc Natl Acad Sci U S A 110, 12414-9
23836654   Curated Info

22

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

23

Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21
23312004   Curated Info

24

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

25

DeNardo BD, et al. (2013) Quantitative phosphoproteomic analysis identifies activation of the RET and IGF-1R/IR signaling pathways in neuroblastoma. PLoS One 8, e82513
24349301   Curated Info

26

Casado P, et al. (2013) Phosphoproteomics data classify hematological cancer cell lines according to tumor type and sensitivity to kinase inhibitors. Genome Biol 14, R37
23628362   Curated Info

27

Imami K, et al. (2012) Temporal profiling of lapatinib-suppressed phosphorylation signals in EGFR/HER2 pathways. Mol Cell Proteomics 11, 1741-57
22964224   Curated Info

28

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

29

Alcolea MP, et al. (2012) Phosphoproteomic analysis of leukemia cells under basal and drug-treated conditions identifies markers of kinase pathway activation and mechanisms of resistance. Mol Cell Proteomics 11, 453-66
22547687   Curated Info

30

Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70
22496350   Curated Info

31

Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25
22424773   Curated Info

32

Rikova K (2012) CST Curation Set: 14275; Year: 2012; Biosample/Treatment: cell line, Tumor pilot study 2mg/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

33

Guo A (2012) CST Curation Set: 13865; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

34

Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56
22115753   Curated Info

35

Lundby A, et al. (2012) Quantitative maps of protein phosphorylation sites across 14 different rat organs and tissues. Nat Commun 3, 876
22673903   Curated Info

36

Guo A (2011) CST Curation Set: 12034; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpTP
Curated Info

37

Hsu PP, et al. (2011) The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332, 1317-22
21659604   Curated Info

38

Guo A (2011) CST Curation Set: 12065; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

39

Guo A (2011) CST Curation Set: 11890; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

40

Ståhl S, et al. (2011) Phosphoproteomic profiling of NSCLC cells reveals that ephrin B3 regulates pro-survival signaling through Akt1-mediated phosphorylation of the EphA2 receptor. J Proteome Res 10, 2566-78
21413766   Curated Info

41

Santamaria A, et al. (2011) The Plk1-dependent phosphoproteome of the early mitotic spindle. Mol Cell Proteomics 10, M110.004457
20860994   Curated Info

42

Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3
21406692   Curated Info

43

Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5
21712546   Curated Info

44

Herskowitz JH, et al. (2010) Phosphoproteomic Analysis Reveals Site-Specific Changes in GFAP and NDRG2 Phosphorylation in Frontotemporal Lobar Degeneration. J Proteome Res 9, 6368-79
20886841   Curated Info

45

Wang YT, et al. (2010) An informatics-assisted label-free quantitation strategy that depicts phosphoproteomic profiles in lung cancer cell invasion. J Proteome Res 9, 5582-97
20815410   Curated Info

46

Possemato A (2010) CST Curation Set: 10722; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P , PTMScan(R) PLK Binding Motif (SpTP) Immunoaffinity Beads Cat#: 1995
Curated Info

47

Iliuk AB, et al. (2010) In-depth analyses of kinase-dependent tyrosine phosphoproteomes based on metal ion-functionalized soluble nanopolymers. Mol Cell Proteomics 9, 2162-72
20562096   Curated Info

48

Possemato A (2010) CST Curation Set: 10111; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

49

Possemato A (2010) CST Curation Set: 10110; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

50

Beausoleil S (2010) CST Curation Set: 10285; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

51

Beausoleil S (2010) CST Curation Set: 10284; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

52

Possemato A (2010) CST Curation Set: 10051; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXS*P, S*PXK/R) Immunoaffinity Beads Cat#: 1982
Curated Info

53

Christensen GL, et al. (2010) Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics 9, 1540-53
20363803   Curated Info

54

Schreiber TB, et al. (2010) An integrated phosphoproteomics work flow reveals extensive network regulation in early lysophosphatidic acid signaling. Mol Cell Proteomics 9, 1047-62
20071362   Curated Info

55

Guo A (2010) CST Curation Set: 9888; Year: 2010; Biosample/Treatment: cell line, no cells/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

56

Guo A (2010) CST Curation Set: 9884; Year: 2010; Biosample/Treatment: cell line, no cells/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

57

Guo A (2010) CST Curation Set: 9885; Year: 2010; Biosample/Treatment: cell line, no cells/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

58

Guo A (2010) CST Curation Set: 9886; Year: 2010; Biosample/Treatment: cell line, no cells/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

59

Guo A (2010) CST Curation Set: 9887; Year: 2010; Biosample/Treatment: cell line, no cells/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

60

Possemato A (2010) CST Curation Set: 9732; Year: 2010; Biosample/Treatment: cell line, H1650/Phenformin; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

61

Possemato A (2010) CST Curation Set: 9349; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)Xp[ST](I/L/V)
Curated Info

62

Han G, et al. (2010) Phosphoproteome analysis of human liver tissue by long-gradient nanoflow LC coupled with multiple stage MS analysis. Electrophoresis 31, 1080-9
20166139   Curated Info

63

Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3
20068231   Curated Info

64

Pan C, Olsen JV, Daub H, Mann M (2009) Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 8, 2796-808
19651622   Curated Info

65

Possemato A (2009) CST Curation Set: 7415; Year: 2009; Biosample/Treatment: cell line, NCI-H3255/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

66

Possemato A (2009) CST Curation Set: 7416; Year: 2009; Biosample/Treatment: cell line, NCI-H3255/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

67

Possemato A (2009) CST Curation Set: 7410; Year: 2009; Biosample/Treatment: cell line, NCI-H2228/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

68

Possemato A (2009) CST Curation Set: 7408; Year: 2009; Biosample/Treatment: cell line, HepG2/untreated; Disease: hepatocellular carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

69

Possemato A (2009) CST Curation Set: 7409; Year: 2009; Biosample/Treatment: cell line, NCI-H2228/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

70

Possemato A (2009) CST Curation Set: 7407; Year: 2009; Biosample/Treatment: cell line, HepG2/untreated; Disease: hepatocellular carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

71

Van Hoof D, et al. (2009) Phosphorylation dynamics during early differentiation of human embryonic stem cells. Cell Stem Cell 5, 214-26
19664995   Curated Info

72

Gauci S, et al. (2009) Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach. Anal Chem 81, 4493-501
19413330   Curated Info

73

Nagano K, et al. (2009) Phosphoproteomic analysis of distinct tumor cell lines in response to nocodazole treatment. Proteomics 9, 2861-74
19415658   Curated Info

74

Chen RQ, et al. (2009) CDC25B mediates rapamycin-induced oncogenic responses in cancer cells. Cancer Res 69, 2663-8
19276368   Curated Info

75

Guo A (2008) CST Curation Set: 5301; Year: 2008; Biosample/Treatment: cell line, MKN-45/serum starved; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

76

Tsai CF, et al. (2008) Immobilized metal affinity chromatography revisited: pH/acid control toward high selectivity in phosphoproteomics. J Proteome Res 7, 4058-69
18707149   Curated Info

77

Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7
18669648   Curated Info

78

Thingholm TE, et al. (2008) TiO2-Based Phosphoproteomic Analysis of the Plasma Membrane and the Effects of Phosphatase Inhibitor Treatment. J Proteome Res 7, 3304-3313
18578522   Curated Info

79

Ruse CI, et al. (2008) Motif-specific sampling of phosphoproteomes. J Proteome Res 7, 2140-50
18452278   Curated Info

80

McNulty DE, Annan RS (2008) Hydrophilic interaction chromatography reduces the complexity of the phosphoproteome and improves global phosphopeptide isolation and detection. Mol Cell Proteomics 7, 971-80
18212344   Curated Info

81

Moritz A (2008) CST Curation Set: 4207; Year: 2008; Biosample/Treatment: cell line, NCI-H1703/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

82

Cantin GT, et al. (2008) Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient phosphoproteomic analysis. J Proteome Res 7, 1346-51
18220336   Curated Info

83

Zahedi RP, et al. (2008) Phosphoproteome of resting human platelets. J Proteome Res 7, 526-34
18088087   Curated Info

84

Imami K, et al. (2008) Automated Phosphoproteome Analysis for Cultured Cancer Cells by Two-Dimensional NanoLC-MS Using a Calcined Titania/C18 Biphasic Column. Anal Sci 24, 161-6
18187866   Curated Info

85

Wang Y, et al. (2007) Profiling signaling polarity in chemotactic cells. Proc Natl Acad Sci U S A 104, 8328-33
17494752   Curated Info

86

Molina H, et al. (2007) Global proteomic profiling of phosphopeptides using electron transfer dissociation tandem mass spectrometry. Proc Natl Acad Sci U S A 104, 2199-204
17287340   Curated Info

87

Yang F, et al. (2006) Phosphoproteome profiling of human skin fibroblast cells in response to low- and high-dose irradiation. J Proteome Res 5, 1252-60
16674116   Curated Info

88

Beausoleil SA, et al. (2004) Large-scale characterization of HeLa cell nuclear phosphoproteins. Proc Natl Acad Sci U S A 101, 12130-5
15302935   Curated Info